Literature DB >> 6126475

A therapeutic and discontinuation study of clobazam and diazepam in anxiety neurosis.

Y D Lapierre, A Tremblay, A Gagnon, P Monpremier, H Berliss, L K Oyewumi.   

Abstract

The efficacy and safety of clobazam and diazepam were compared in 40 patients with generalized anxiety disorder in a 28 day non-placebo-controlled trial followed by a 3-day single-blind placebo washout. The two drugs were equally anxiolytic, and the anxiety symptoms of most patients were brought under control within 1 week. Both drugs were found to be nontoxic. Diazepam had slightly greater sedative properties than clobazam, which was the patients' preferred drug after 28 days of treatment. During placebo washout, anxiety returned to pretreatment levels. Abrupt withdrawal did not result in rebound phenomena.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6126475

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

1.  Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care.

Authors:  K G Power; R J Simpson; V Swanson; L A Wallace
Journal:  Br J Gen Pract       Date:  1990-07       Impact factor: 5.386

Review 2.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

Review 3.  Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential.

Authors:  Karen J Gregory; Elizabeth N Dong; Jens Meiler; P Jeffrey Conn
Journal:  Neuropharmacology       Date:  2010-07-14       Impact factor: 5.250

4.  Changes in "withdrawal symptoms" following discontinuation of low-dose diazepam.

Authors:  P Hayward; J Wardle; A Higgitt; J Gray
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

Review 5.  The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders.

Authors:  Daniel Peterlik; Peter J Flor; Nicole Uschold-Schmidt
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.